Livforsakringsbolaget Skandia Omsesidigt Purchases Shares of 111,158 Exelixis, Inc. $EXEL

Key Points

• Livforsakringsbolaget Skandia Omsesidigt has acquired a new stake in Exelixis, Inc., purchasing 111,158 shares valued at approximately $4.9 million.
• Exelixis reported an EPS of $0.75 for the latest quarter, surpassing the consensus estimate by $0.12, with revenue totaling $568.26 million.
• The stock has a current market capitalization of $10.50 billion, with a consensus rating of "Moderate Buy" from analysts and a consensus price target of $44.06.

Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 111,158 shares of the biotechnology company's stock, valued at approximately $4,900,000.

A number of other hedge funds have also recently bought and sold shares of the stock. Frank Rimerman Advisors LLC increased its position in shares of Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company's stock worth $234,000 after purchasing an additional 285 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 307 shares in the last quarter. Rathbones Group PLC increased its position in shares of Exelixis by 5.3% during the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company's stock worth $253,000 after purchasing an additional 347 shares in the last quarter. Larson Financial Group LLC increased its position in shares of Exelixis by 9.2% during the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company's stock worth $161,000 after purchasing an additional 367 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Exelixis by 14.8% during the 1st quarter. Smartleaf Asset Management LLC now owns 3,378 shares of the biotechnology company's stock worth $124,000 after purchasing an additional 436 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL stock opened at $39.01 on Tuesday. The company has a market capitalization of $10.50 billion, a P/E ratio of 18.75, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company's 50 day moving average price is $39.87 and its two-hundred day moving average price is $39.66. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to the consensus estimate of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business's quarterly revenue was down 10.8% on a year-over-year basis. During the same period last year, the company posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Bank of America increased their price objective on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday, June 5th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Stifel Nicolaus raised their target price on shares of Exelixis from $38.00 to $41.00 and gave the company a "hold" rating in a research note on Tuesday, July 29th. Finally, Barclays lifted their price objective on shares of Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Exelixis has a consensus rating of "Moderate Buy" and a consensus price target of $44.06.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.